RxDoctor Payments Data

Janice Plaxe, DO

Internal Medicine · Boca Raton, FLNPI 1326144825

Payments from drug & device makers

$4,631in general payments, 2019–2025

Across 247 payments — averaging $18.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$704
  • AbbVie$477
  • Johnson & Johnson$458
  • Abbott$320
  • Astellas Pharma US Inc$282
  • Amarin Pharma, Inc.$189
  • plus $2K from 38 others

What the payments were for

  • Consulting fees$150%
  • Food & beverage$4,617100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,631 in reported general payments places this provider in the 85th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$505,286
Medicare patients
434
Services billed
18,440

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban38$48,098
Repatha SureclickEvolocumab31$37,632
OzempicSemaglutide20$31,493
XareltoRivaroxaban22$26,200
Repatha SyringeEvolocumab18$19,637
JardianceEmpagliflozin11$17,447
Breo ElliptaFluticasone/Vilanterol11$5,210
Ezetimibe141$4,915
Rosuvastatin Calcium337$4,531
Levothyroxine Sodium329$4,022
SynthroidLevothyroxine Sodium54$3,611
Simvastatin186$2,342
Losartan Potassium198$1,892
Atorvastatin Calcium172$1,451
Escitalopram Oxalate85$1,347

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$50$48,09838 claims
Novo NordiskOzempic$166$31,49320 claims
Johnson & JohnsonXarelto$458$26,20022 claims
Boehringer IngelheimJardiance$14$17,44711 claims
GSKBreo Ellipta$130$5,21011 claims
AbbVieSynthroid$477$3,61154 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Boca Raton

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →